^
Association details:
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
Published date:
02/24/2022
Excerpt:
Pancreatic Adenocarcinoma...Useful in certain circumstances...Rucaparib (for germline or somatic BRCA1/2 or PALB2 mutations)
Evidence Level:
Sensitive: C1 - Off-label
  (Approved for Peritoneal Cancer)
New
Excerpt:
RUBRACA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated...for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated epithelial ovarian, fallopian tube, or primary peritoneal cancer who have been treated with two or more chemotherapies.